DrugDev to Sponsor and Speak at Disruptive Innovation Conference on September 10-11 in Boston to Continue the Conversation of Clinical Trial Innovation

Share Article

DrugDev’s President and CEO Ibs Mahmood to discuss strategies to reinvent the clinical trial; Advisory Board Chair Dr. Jeffrey Kasher to lead panel on the CRO of the future

Ibraheem Mahmood, President and CEO, DrugDev

DrugDev is driving clinical research innovation through industry-wide collaboration, standardization, and a beautiful technology experience.

DrugDev will promote the adoption of modern technology to lower the cost and upgrade the efficiency of clinical trials with its executive sponsorship and participation in the Disruptive Innovations US (DPharm) conference, September 10-11 in Boston.

DrugDev President and CEO Ibraheem (Ibs) Mahmood will discuss the critical need to standardize, collaborate and deliver a beautiful technology experience for all stakeholders including patients during the “Interview Segment with Change Agents for Industry” session led by Andreas Koester, MD, PhD, VP Innovation, R&D Operations, Janssen and Komathi Stem, MS, Strategic Innovation Leader, Genentech/Roche.

Also at DPharm, Dr. Jeffrey Kasher, Chair of the DrugDev Advisory Board and President of Patients Can’t Wait, will lead a panel discussion, “Disrupting the CRO: What Will Be the CRO of the Future?” Participants will include Andrew Lee, MD, SVP, Head of Global Clinical Trial Operations, Merck; Solomon Babani, MBA, Global VP, Alliance Management, Covance; Paul Colvin, RPH, EVP, Global Clinical Development, PPD; Jamie Macdonald, CEO, INC Research; and, Adrian McKemey, PhD, SVP and Managing Director, Advisory Services, Quintiles.

To learn more about how DrugDev is driving clinical research innovation through industry-wide collaboration, standardization, and a beautiful technology experience, visit drugdev.com.

About DrugDev
DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry (launching this year). Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at drugdev.com - and connect with DrugDev on LinkedIn and Twitter to join the conversation.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty
DrugDev
+1 617-688-3253
Email >

Kristopher Sarajian
DrugDev
617-952-4071 132
Email >
@drugdevinc
Follow >
Visit website